| P/E (FY) | — | Sales (TTM) | €43.63B |
| Earnings (TTM) | €7.81B | ROE | 10.50% |
| Net Margin | 17.91% | ROIC | — |
| Debt / Equity | 0.26 | TD / EBITDA | — |
| EPS Growth 3Y | −1.47% | Sales Growth 3Y | 5.03% |
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides treatments across immunology and inflammation, rare diseases, neurology, and oncology, as well as vaccines including pediatric, respiratory syncytial virus, and hexavalent combination vaccines. The company has collaboration and license agreements with partners such as Exscientia, ABL Bio, Innate Pharma, Atomwise, Insilico Medicine, and Kymera Therapeutics to develop novel oncology, immunology, and neurology programs.
| Market Cap | — | Trading Days | 6056 |
| 52W High | 52.68 |
| 52W Low | 40.89 |
| % Off High | −18.58% |
| YTD | −6.58% | 1Y | −8.08% |
| 3Y | −7.67% | 5Y | 6.83% |
| 10Y | 57.70% | Since incept. (ann.) | 5.51% |
| Ann. Volatility (1Y) | 26.66% | Ann. Volatility (3Y) | 26.15% |
| Sharpe (1Y) | −0.19 | Sharpe (3Y) | 0.03 |
| Max Drawdown (1Y) | −16.70% | Max Drawdown (3Y) | −23.37% |
| Beta (3Y, vs SPY) | 0.04 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| LLY | ELI LILLY & Co | $1.14T | 52.7 |
| JNJ | JOHNSON & JOHNSON | $639.90B | 24.1 |
| ONC | BeOne Medicines Ltd. | $472.90B | 1722.2 |
| ABBV | AbbVie Inc. | $465.20B | 111.6 |
| MRK | Merck & Co., Inc. | $321.97B | 17.9 |
| ABT | ABBOTT LABORATORIES | $188.12B | 29.0 |
| PFE | PFIZER INC | $143.34B | 18.5 |
| BMY | BRISTOL MYERS SQUIBB CO | $128.90B | 18.2 |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $122.67B | 31.5 |
| REGN | REGENERON PHARMACEUTICALS, INC. | $65.34B | 16.8 |
| TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | $40.45B | 28.7 |
| ALNY | ALNYLAM PHARMACEUTICALS, INC. | $38.35B | 123.0 |